Table 1.
Demographics and baseline characteristics of the enrolled patients
| Phase 1a (N = 29) |
Phase 1b | ||
|---|---|---|---|
| Sugemalimab monotherapy (N = 69) | Sugemalimab in combination with chemotherapy (N = 109) | ||
| Age (years) | 53 (23–75) | 55 (25–73) | 60 (23–75) |
| Sex | |||
| Male | 18 (62.1) | 38 (55.1) | 83 (76.1) |
| Female | 11 (37.9) | 31 (44.9) | 26 (23.9) |
| Weight at baseline (kg) | 59.2 (41.0–78.0) | 58.0 (39.0–81.0) | 58.4 (42.0–104.0) |
| ECOG | |||
| 0 | 4 (13.8) | 23 (33.3) | 38 (34.9) |
| 1 | 25 (86.2) | 45 (65.2) | 71 (65.1) |
| Missing | 0 | 1 (1.4) | 0 |
| Current cancer stage | |||
| Stage III | 0 | 0 | 1 (0.9) |
| Stage IIIA | 0 | 0 | 2 (1.8) |
| Stage IIIB | 0 | 1 (1.4) | 8 (7.3) |
| Stage IIIC | 0 | 0 | 2 (1.8) |
| Stage IV | 26 (89.7) | 58 (84.1) | 83 (76.1) |
| Stage IVA | 1 (3.4) | 1 (1.4) | 3 (2.8) |
| Stage IVB | 1 (3.4) | 9 (13.0) | 10 (9.2) |
| Missing | 1 (3.4) | 0 | 0 |
| Number of prior therapy received | 2 (0–7) | 1 (0–9) | 0 (0–2) |
Data are median (range) or n (%)
ECOG, Eastern Cooperative Oncology Group